- SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
-
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
- -
-
Paragraph 00297; 00309-00310; 00815
(2021/04/01)
-
- Microwave use of amidine compounds in the aqueous phase benzoate synthesis of benzimidazole compounds method
-
The invention discloses a microwave the use of amidine compounds in the aqueous phase benzoate synthesis of benzimidazole compounds, in the aqueous phase under microwave conditions adding benzoic amidine compound under alkaline condition [...] into benzimidazole reaction, invention an environment-friendly, the operation is simple, cheap and safe, efficient process for preparing benzimidazole method. Compared with the prior art, this method not only can be applied to a large number of functional groups, the productive rate is high, few by-products, and the operation is simple, safe, low cost, environmental protection; .
- -
-
Paragraph 0074
(2019/03/28)
-
- STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
-
The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.
- -
-
Paragraph 00697
(2017/01/09)
-
- PRMT5 INHIBITORS AND USES THEREOF
-
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described
- -
-
Paragraph 00420
(2014/07/08)
-
- SERINE/THREONINE PAK1 INHIBITORS
-
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
- -
-
Page/Page column 108
(2013/03/26)
-
- BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN
-
The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 199
(2013/12/03)
-
- ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS
-
Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
- -
-
Page/Page column 41
(2008/06/13)
-
- ARYLSULFONYL BENZYL ETHERS AS 5-HT2A ANTAGONISTS
-
Compounds of formula (I) are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.
- -
-
Page/Page column 23
(2010/11/23)
-
- DIARYLSULFONES AS 5-HT2A ANTAGONISTS
-
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
- -
-
Page/Page column 76
(2008/06/13)
-